Merus drug, with immunotherapy, shows preliminary survival boost for patients with head and neck cancer
A Merus drug, combined with Keytruda, shows preliminary survival gains in newly diagnosed metastatic head and neck cancer
Related Articles
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead’s CEO says he’s committed to making sure people around the world can get his firm’s new HIV prevention shot Yeztugo.
Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
A rivalry between two drugmakers, Cogent Biosciences and Blueprint Medicines, has turned ugly.
Top gene therapy regulator forced out at FDA
Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy Rachael Anatol have been
U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service
A U.K. health agency said the Alzheimer’s drugs Kisunla and Leqembi are not cost-effective, meaning they won’t be offered through the NHS.
Brain implant captures speech tone, pitch through analyzing activity
New brain-computer interface reduced time lag in translating thoughts into speech in a meaningful advance for the field.
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead’s CEO says he’s committed to making sure people around the world can get his firm’s new HIV prevention shot Yeztugo.
FDA’s gene therapy turmoil, and an alternative model for funding research
Why did the Food and Drug Administration suddenly oust one of its top gene therapy regulators?
Curbing the overdose crisis requires professional standards, patient safety
Two advocates demand systemic change in addiction treatment that prioritizes safety and accountability above all else.
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead’s CEO says he’s committed to making sure people around the world can get his firm’s new HIV prevention shot Yeztugo.
Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
A rivalry between two drugmakers, Cogent Biosciences and Blueprint Medicines, has turned ugly.